| Literature DB >> 32415125 |
Yi-Ran Tu1, Tsung-Yu Tsai1,2, Ming-Shyan Lin3, Kun-Hua Tu1,2, Cheng-Chia Lee1,2, Victor Chien-Chia Wu4, Hsiang-Hao Hsu1, Ming-Yang Chang1, Ya-Chung Tian1, Chih-Hsiang Chang5,6.
Abstract
To date, few studies have been conducted to pairwise compare the prognosis of peritoneal dialysis (PD), unplanned PD, and unplanned hemodialysis (HD). We analyzed longitudinal data from Taiwan's National Health Insurance Research Database. We included 45,165 patients whose initial dialytic modality was PD or unplanned HD between January 1, 2001 and December 31, 2013. We divided the patients into three groups according to their initial dialytic modalities. The primary outcomes were all-cause mortality and death from infection during 1-year follow up. The risks of all-cause mortality and infection death were higher in the unplanned PD group than in the planned PD group (hazard ratio [HR] 1.43, 95% confidence interval [CI] 1.28-1.60; HR 1.54, 95% CI 1.32-1.80). Likewise, the risks of all-cause mortality and infection death were higher in the unplanned HD group (HR 1.64, 95% CI 1.48-1.82; HR 1.85, 95% CI 1.61-2.13). Furthermore, the risks of all-cause mortality and infection death were also higher in the unplanned HD group than in the unplanned PD group (HR 1.15, 95% CI 1.07-1.23; HR 1.20, 95% CI 1.09-1.32). In conclusion, our study demonstrates that patients whose initial modality was planned PD or unplanned PD may have better clinical outcomes than those whose initial modality was unplanned HD.Entities:
Mesh:
Year: 2020 PMID: 32415125 PMCID: PMC7229162 DOI: 10.1038/s41598-020-64986-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Baseline characteristics of patients.
| Variable | Planned PD ( | Unplanned PD ( | Unplanned HD ( | ||
|---|---|---|---|---|---|
| Demographic | |||||
| Age (years) | 54.6 ± 14.4 | 54.2 ± 15.9 | 67.8 ± 14.0 | <0.001 | 0.035 |
| Age ≥ 65 years | 1,679 (24.9) | 2,228 (26.0) | 15,653 (60.8) | <0.001 | 0.089 |
| Male | 3,044 (45.1) | 4,147 (48.5) | 12,690 (49.3) | <0.001 | 0.868 |
| No. of prior nephrologist outpatient visit in the previous year | 13.9 ± 9.3 | 9.7 ± 8.9 | 8.5 ± 8.6 | <0.001 | 0.001 |
| Monthly income, NTD | <0.001 | 0.965 | |||
| 0 - 17,880 | 2,238 (33.2) | 2,900 (33.9) | 10,444 (40.5) | ||
| 17,881 – 22,800 | 2,104 (31.2) | 2,734 (32.0) | 9,407 (36.5) | ||
| >22,800 | 2,404 (35.6) | 2,921 (34.1) | 5,911 (22.9) | ||
| Comorbidity | |||||
| Hypertension | 5,486 (81.3) | 7,417 (86.7) | 23,417 (90.9) | <0.001 | 0.971 |
| Diabetes mellitus | 2,373 (35.2) | 3,585 (41.9) | 16,869 (65.5) | <0.001 | 0.890 |
| Chronic obstructive pulmonary disease | 278 (4.1) | 342 (4.0) | 2,717 (10.5) | <0.001 | 0.114 |
| Peripheral arterial disease | 140 (2.1) | 216 (2.5) | 1,400 (5.4) | <0.001 | 0.815 |
| Ischemic heart disease | 1,058 (15.7) | 1,757 (20.5) | 8,566 (33.3) | <0.001 | 0.107 |
| Polycystic kidney disease | 170 (2.5) | 126 (1.5) | 368 (1.4) | <0.001 | 0.598 |
| History of event | |||||
| History of heart failure | 774 (11.5) | 1,601 (18.7) | 9,311 (36.1) | <0.001 | 0.001 |
| Previous ischemic stroke | 550 (8.2) | 853 (10.0) | 6,194 (24.0) | <0.001 | 0.306 |
| Previous hemorrhage stroke | 95 (1.4) | 177 (2.1) | 1,042 (4.0) | <0.001 | 0.655 |
| Old myocardial infarction | 198 (2.9) | 439 (5.1) | 2,854 (11.1) | <0.001 | 0.035 |
| CCI score | 3.5 ± 1.7 | 3.9 ± 1.9 | 5.1 ± 2.0 | <0.001 | 0.126 |
| Medications | |||||
| Antiplatelet | 1,087 (16.1) | 1,717 (20.1) | 8,588 (33.3) | <0.001 | 0.435 |
| ACEi/ARB | 3,269 (48.5) | 4,867 (56.9) | 12,445 (48.3) | <0.001 | 0.158 |
| Beta-blocker | 3,597 (53.3) | 4,716 (55.1) | 12,399 (48.1) | <0.001 | 0.012 |
| Loop diuretics | 3,340 (49.5) | 5,186 (60.6) | 14,953 (58.0) | <0.001 | 0.300 |
| Oral hypoglycemic agent | 1,358 (20.1) | 2,070 (24.2) | 9,305 (36.1) | <0.001 | 0.614 |
| Insulin | 1,081 (16.0) | 1,496 (17.5) | 6,702 (26.0) | <0.001 | 0.749 |
| Statin | 1,966 (29.1) | 2,257 (26.4) | 5,873 (22.8) | <0.001 | 0.665 |
| Follow-up duration (years) | 5.0 ± 3.7 | 4.3 ± 3.4 | 2.1 ± 2.1 | <0.001 | 0.402 |
PD, peritoneal dialysis; HD, hemodialysis; NTD, national Taiwan dollar; CCI, Charlson comorbidity index; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker;
#Adjusted for multiple propensity scores;
Data were presented as frequency (percentage) or mean ± standard deviation.
Time to event outcome analysis during the 1-year follow up.
| Outcome | Number of event (%) | Adjusted HR or SHR (95% CI) # | ||||
|---|---|---|---|---|---|---|
| Planned PD ( | Unplanned PD ( | Unplanned HD ( | Unplanned PD vs. Planned PD (reference) | Unplanned HD vs. Planned PD (reference) | Unplanned HD vs. Unplanned PD (reference) | |
| All-cause mortality | 475 (7.0) | 1,018 (11.9) | 6,975 (27.1) | 1.43 (1.28–1.60)* | 1.64 (1.48–1.82)* | 1.15 (1.07–1.23)* |
| Infection death | 241 (3.6) | 556 (6.5) | 4,215 (16.4) | 1.50 (1.29–1.75)* | 1.82 (1.58–2.10)* | 1.21 (1.10–1.34)* |
| MACCE§ | 413 (6.1) | 812 (9.5) | 5,310 (20.6) | 1.29 (1.14–1.46)* | 1.61 (1.45–1.80)* | 1.25 (1.15–1.36)* |
| All-cause admission | 3,133 (46.4) | 4,601 (53.8) | 16,079 (62.4) | 1.18 (1.13–1.23)* | 1.31 (1.25–1.37)* | 1.11 (1.07–1.16)* |
PD, peritoneal dialysis; HD, hemodialysis; HR, hazard ratio; SHR, subdistribution hazard ratio; MACCE, major adverse cardiac and cerebrovascular event;
§Including acute myocardial infarction, acute ischemic stroke, intracerebral hemorrhage, heart failure, or cardiovascular death;
#Adjusted for multiple propensity scores, age, number of prior nephrologist outpatient visit in the previous year, dementia, heart failure, myocardial infarction, use of proton pump inhibitor and use of beta-blocker;
*P value < 0.05;
Data were presented as frequency (percentage).
Figure 1Direct-adjusted (predicted) survival of all-cause mortality (A) and major cardiac and cerebrovascular events (C), and direct-adjusted cumulative incidence function of infection death (B) and all-cause readmission (D) among patients with different initial dialytic modalities during the 1-year follow-up.
Figure 2Patient inclusion criteria.